Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration to market Bosentan Tablets for Oral Suspension, 32 mg.
Due to medical necessity and potential drug shortage expectations, the US FDA has provided an exception which enables the Company to supply Atovaquone Oral Suspension USP 750mg/5 to the US market.